VIDEO: MOLTO study probes combination therapy in Richter syndrome
In this video, Jakub Svoboda, MD, discusses updated data on the results of the MOLTO study into Richter syndrome presented at ASCO Annual Meeting.
Svoboda, an associate professor of medicine at Hospital of the University of Pennsylvaniia, highlighted the study, which examined a combination therapy consisting of venetoclax (Venclexta; Genentech, AbbVie), atezolizumab (Tecentriq, Genentech) and obinutuzumab (Gazyva, Genentech) into patients with Richter syndrome, which can be the result of progression from chronic lymphocytic leukemia.
“That is a very challenging situation when CLL transforms into aggressive diffuse large B-cell lymphoma,” Svoboda said. “They’ve had some really good results.”
Reference:
- Frustaci A, et al. Abstract 7502. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Collapse
Read more about